Trial Profile

Phase II trial of perifosine +/- sorafenib in heavily pretreated patients with relapsed/refractory lymphomas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perifosine (Primary) ; Sorafenib
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Focus Biomarker; Pharmacogenomic; Therapeutic Use

Most Recent Events

11 Dec 2012 Final data were presented at the American Society of Hematology annual meeting, according to an Aeterna Zentaris Inc media release.
26 Nov 2012 Status changed to completed based on information reported in an Aeterna Zentaris media release.
26 Nov 2012 Final trial data will be presented at the 2012 Annual Meeting of the American Society of Hematology (ASH-2012) according to an Aeterna Zentaris media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com